FDA Inspection 1202009 — Glynis Ablon, M.D.
The FDA completed an inspection of Glynis Ablon, M.D. on March 24, 2023 in Manhattan Beach, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 24, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Manhattan Beach, CA (United States)
Additional Details
Clinical Investigator (CI)